Decoy Therapeutics Inc. (DCOY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has a cash flow conversion efficiency ratio of -0.745x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($3.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DCOY net asset quality score to measure how much of total assets are equity-financed.
Decoy Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Decoy Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore DCOY debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Decoy Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Decoy Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Literacy Capital PLC
LSE:BOOK
|
-0.008x |
|
Treatt PLC
LSE:TET
|
0.018x |
|
Netmedia Group S.A.
PA:ALNMG
|
-1.917x |
|
UNITED OIL+GAS PLC LS-01
F:1UO
|
N/A |
|
Shrenik Limited
NSE:SHRENIK
|
0.003x |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
-0.002x |
|
Oryx International Growth Fund
LSE:OIG
|
0.003x |
|
iOThree Limited Ordinary Shares
NASDAQ:IOTR
|
N/A |
Annual Cash Flow Conversion Efficiency for Decoy Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Decoy Therapeutics Inc. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see DCOY stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.89 Million | $-4.83 Million | -0.820x | +72.62% |
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -121.23% |
| 2014-12-31 | $-6.54 Million | $-6.93 Million | 1.060x | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more